Bruce Kreter Email & Phone Number

Foster City, Ca, Us

My progressive roles at Gilead Sciences culminated in my current leadership position as Executive Director of Medical Affairs for Global Liver Diseases. Reporting to the VP of Global Medical Affairs and managing 15 global employees based in the EU and US, I am accountable for the medical planning and medical content for HCV, HBV, NASH, and PSC. I connect with international KOLs on a peer basis to develop plans to execute public health initiatives and patient education programs. I also collaborate with my intercontinental colleagues on data generation, health economics, scientific communications, and medical content creation.𝗞𝗲𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 – Initiated a strategic RFP process to submit and approve investigator-sponsored trials. This process—now a standard operating procedure across therapeutic areas—significantly increased the scope and quality of clinical trial proposals by taking a proactive approach in the ISRs that Gilead supports. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀GLOBAL PUBLIC HEALTH: Engaged with in-country staff to interface with policy makers and health ministries to enact new policies surrounding liver disease elimination. PRODUCT LIFECYCLE MANAGEMENT: Co-chair HCV Lifecycle Committee to ensure long-term strategic cross-functional plans aligned to unmet patient medical needs. AI / MACHINE LEARNING FOR HCV SCREENING: Initiated and launched an AI/Machine Learning algorithm that identifies likely candidates, expected to reduce the number needed to be screened by 10-25-fold.

Foster City, Ca, Us

As Executive Director of Global Medical Affairs for the HCV division, a key aspect of my role was to differentiate single-tablet HCV regimens from the competition and institute HCV elimination programs aligned to WHO 2030 objectives. 𝗞𝗲𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 – Following the launches of our HCV medications, we maintained a majority market share worldwide by creating a differentiation platform grounded in science to inform physicians on the efficacy, safety, and appropriate use of our products.𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀TEAM LEADERSHIP: Managed a global team to engage the international hepatology community in supporting access to HCV care. CUSTOMER INSIGHTS: Ensured the safe and effective use of products, navigating complex healthcare systems in US, EU, and AsiaPacific.

Foster City, Ca, Us

I led the HCV Medical Affairs launch strategy in the US and Japan, and coordinated the medical communications strategies with EU for two of our most successful drugs. In addition, through strategic collaboration with health economics, outcomes research, R&D, marketing, sales, and government affairs teams, we coordinated cross-functional engagement plans for launch. 𝗞𝗲𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 – Introduced the first-ever “one-pill-a-day” single-tablet regimen to cure Hep C in 12 weeks with >95% success rate across all populations. Treatment has helped eliminate Hep C in more than 5 million patients around the world. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀NEW PRODUCT LAUNCH: Introduced four new drugs in four years, each better than the previous standard of care. EXECUTIVE INFLUENCE: Pivoted enterprise to flagship product with more effective differentiation strategies supporting HCV treatment selection.

Foster City, Ca, Us

Lawrence Township, Nj, Us

I led the medical alignment strategy for the US launch of a new kidney transplant drug, working closely with the product launch team and field medical science liaisons (MSLs) to create the internal launch communications and training materials, including implementation of a comprehensive Risk Evaluation and Mitigation Strategy (REMS).𝗞𝗲𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 – Garnered additional clinical trial investment to address unmet medical needs and develop data-generation strategy to support perceived usage.

Lawrence Township, Nj, Us

I joined Bristol-Myers Squibb in 2001 as the Medical Director of Global Medical Affairs for Hepatitis B, a role I held until 2009, when I was promoted to Group Director of Global Medical Affairs for the entire Viral Hepatitis division, including HCV.𝗞𝗲𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 – Spearheaded a global study demonstrating that long-term administration of Baraclude resulted in reversal of cirrhosis, the late-stage scarring of the liver after hepatitis. Secured a label change to the EU SMPC and published the results in a major medical journal, Hepatology. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀STRATEGIC PLANNING: Contributed directly to product development strategy as a core member of the clinical project team.INTERNATIONAL LEADERSHIP: Led global advisory board for eight years, working with key opinion leaders in the US, China, Japan, Europe, Latin America, and Africa.CROSS-FUNCTIONAL TEAM: Developed a long-term strategic approach in partnership with Clinical, Regulatory, and Commercial teams.

Raleigh, North Carolina, Us

Lawrence Township, Nj, Us

Pharmd, Clinical Pharmacy

Pharmaceutical & Biotechnology Industry; Leading In Professional Service Firms

Bachelor Of Science (B.S.), Biological Sciences

Bachelor Of Arts (B.A.), Psychology